Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $3.8 million
Deal Type : Financing
Release Therapeutics Secures CHF 3.3 Million in Seed Funding
Details : The financing is intended to support the initial preclinical stages to advance the clinical development of the company's lead product for treating patients with metachromatic leukodystrophy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 08, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $3.8 million
Deal Type : Financing